Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
715 (USA) · Dr. Moreau
consented 2013-02-17
AEs
1
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate SINUS BRADYCARDIA — outcome: RECOVERED/RESOLVED; onset 2013-03-18 (study day 30.0); relationship: NONE
Data queries
No data queries.